How do I interpret a von Willebrand disease panel (VWF antigen, VWF ristocetin cofactor activity, factor VIII level, and multimer analysis)?

How to Interpret a Von Willebrand Disease Panel

Begin by ordering the three core tests simultaneously—VWF antigen (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo or newer GPIb-binding assays), and factor VIII (FVIII)—then calculate the VWF:RCo/VWF:Ag ratio to distinguish quantitative (Type 1) from qualitative (Type 2) defects, reserving multimer analysis only for cases with abnormal initial results or discordant ratios. 1, 2

Step 1: Order the Complete Initial Panel

• Always order all three tests together (VWF:Ag, VWF:RCo or VWF activity, and FVIII) as a simultaneous panel—ordering only one or two tests leads to incomplete diagnosis and misclassification. 1, 2
• VWF:Ag measures the quantity of VWF protein present. 1
• VWF:RCo (or newer VWF:GPIbR/VWF:GPIbM assays) measures the functional activity of VWF for platelet binding. 1, 3
• FVIII activity is frequently reduced in VWD and helps distinguish VWD from hemophilia A. 1, 2

Step 2: Apply Diagnostic Thresholds

• VWF levels <30 IU/dL are the primary cutoff for definitive VWD diagnosis. 1, 2
• This threshold accounts for blood type O individuals (who have ~25% lower baseline VWF levels) and the high frequency of mild bleeding symptoms in the general population. 1
• VWF levels 30–50 IU/dL may still indicate VWD when supported by strong personal or family bleeding history—do not dismiss borderline results without clinical correlation. 1, 2
• Normal range is 50–200 IU/dL. 1

Step 3: Calculate and Interpret the VWF:RCo/VWF:Ag Ratio

This ratio is the critical discriminator between Type 1 and Type 2 VWD:

• Ratio <0.5–0.7 indicates a qualitative defect (Type 2 VWD)—the VWF protein is present but dysfunctional. 1, 2
• Ratio ≥0.7 with proportionally reduced VWF:Ag and VWF:RCo suggests a quantitative defect (Type 1 VWD)—there is simply less VWF, but it functions normally. 4, 1, 2
• The 0.7 cutoff is most commonly recommended, though some guidelines use 0.5–0.7 as a range. 1

Step 4: Classify VWD Type Based on Pattern

Type 1 VWD (Quantitative Deficiency, ~75% of cases)

• VWF:Ag: <30 IU/dL (decreased) 4, 1
• VWF:RCo: <30 IU/dL (proportionally decreased) 4, 1
• FVIII: Normal to decreased 4, 1
• Ratio: >0.7 (normal ratio) 4, 1
• Multimers: Normal pattern 4, 1

Type 1C VWD (Increased Clearance Subtype)

• Same pattern as Type 1, but distinguished by increased VWFpp/VWF:Ag ratio (>3.2) and rapid clearance on DDAVP trial. 4, 5

Type 2A VWD (Loss of High-Molecular-Weight Multimers)

• VWF:Ag: Normal to decreased (30–200 IU/dL) 4, 1
• VWF:RCo: <30 IU/dL (markedly decreased) 4, 1
• FVIII: Normal to decreased 4, 1
• Ratio: <0.7 (discordant) 4, 1
• Multimers: Loss of high-molecular-weight multimers 4, 1
• Additional: Abnormal VWF:CB (collagen binding) 4

Type 2B VWD (Increased Platelet Affinity)

• VWF:Ag: Decreased (30–200 IU/dL) 4, 1
• VWF:RCo: <30 IU/dL (markedly decreased) 4, 1
• FVIII: Normal to decreased 4, 1
• Ratio: Usually <0.7 4, 1
• Multimers: Loss of high-molecular-weight multimers 4, 1
• Additional: Enhanced RIPA (ristocetin-induced platelet aggregation at low concentrations), thrombocytopenia may be present 4, 1

Type 2M VWD (Platelet-Binding Defect, Normal Multimers)

• VWF:Ag: Decreased (30–200 IU/dL) 4, 1
• VWF:RCo: <30 IU/dL (markedly decreased) 4, 1
• FVIII: Normal to decreased 4, 1
• Ratio: <0.7 4, 1
• Multimers: Normal pattern (this distinguishes 2M from 2A) 4, 1
• Additional: Normal VWF:CB (distinguishes from 2A) 4

Type 2N VWD (Factor VIII Binding Defect)

• VWF:Ag: 30–200 IU/dL (normal to mildly decreased) 4, 1
• VWF:RCo: 30–200 IU/dL (normal to mildly decreased) 4, 1
• FVIII: Markedly decreased (<10 IU/dL) 4, 1
• Ratio: >0.7 (normal ratio) 4, 1
• Multimers: Normal pattern 4, 1
• Additional: Decreased VWF:FVIIIB (factor VIII binding assay); mimics hemophilia A 4, 5

Type 3 VWD (Severe, Complete Deficiency)

• VWF:Ag: <3 IU/dL (virtually absent) 4, 1
• VWF:RCo: <3 IU/dL (virtually absent) 4, 1
• FVIII: Markedly decreased (<10 IU/dL) 4, 1
• Ratio: Not applicable 4, 1
• Multimers: Absent 4, 1

Step 5: When to Order Multimer Analysis

Do NOT order multimer analysis as an initial screening test—it is technically complex, expensive, and unnecessary without abnormal initial results. 1, 2

Order multimer analysis only when:

• VWF:RCo is abnormally low 1, 2
• VWF:RCo/VWF:Ag ratio is <0.5–0.7 1, 2
• You need to distinguish between Type 2 subtypes (2A vs. 2B vs. 2M) 4, 6
• Initial results are borderline but clinical suspicion remains high 1, 2

Multimer analysis shows the distribution pattern of VWF multimers and is interpreted qualitatively in conjunction with the initial three tests. 1, 6

Critical Pre-Analytical Factors That Invalidate Results

Patient Factors to Control Before Testing:

• Avoid stress, crying, or anxiety during phlebotomy—these falsely elevate VWF and FVIII levels. 1, 2
• No vigorous exercise immediately before testing. 1
• Avoid testing during acute illness, inflammation, or pregnancy—these conditions can mask VWD by artificially raising VWF levels. 1, 2
• Discontinue estrogen/oral contraceptives if possible before testing, as they elevate VWF. 1, 2
• Document ABO blood type—type O individuals have 25% lower VWF levels than non-O types. 1, 2

Sample Handling Requirements:

• Transport whole blood at room temperature—never refrigerate, as this causes cryoprecipitation of VWF. 1, 2
• Process promptly at room temperature: separate plasma, centrifuge thoroughly to remove platelets, and assay within 2 hours if fresh. 1, 2
• For delayed testing, freeze plasma at ≤−40°C, thaw at 37°C, and keep at room temperature <2 hours before assay. 1, 2
• Expect 10–20% lower FVIII activity in frozen-thawed plasma compared to fresh samples; suboptimal handling worsens this loss. 1, 2

Assay Quality and Variability

• VWF assays have high coefficients of variation (10–30%), especially VWF:RCo, which is the least precise. 1, 2, 3
• Interlaboratory variability is substantial—results from different labs may not be directly comparable. 1, 3
• Newer GPIb-binding assays (VWF:GPIbR, VWF:GPIbM) show better precision than VWF:RCo and are recommended by recent guidelines, though FDA clearance in the U.S. remains limited. 3
• Use WHO-standardized calibrators and report results in IU/dL when possible. 1, 2

Common Pitfalls to Avoid

• Ordering incomplete panels (only VWF:Ag or only FVIII) prevents accurate classification and leads to missed diagnoses. 1, 2
• Using multimer analysis as a first-line test wastes resources and delays diagnosis—reserve it for reflex testing. 1, 2
• Testing during acute illness or pregnancy can normalize VWF levels and mask underlying VWD. 1, 2
• Improper sample handling (refrigeration, delayed processing) invalidates results and necessitates repeat testing. 1, 2
• Failing to repeat testing in borderline cases (30–50 IU/dL)—VWF levels fluctuate, and a single normal result does not exclude VWD in symptomatic patients. 1, 2
• Ignoring blood type O status—these patients have physiologically lower VWF and may not have true VWD despite levels in the 30–50 range. 1, 2

Tests NOT Recommended for Routine Screening

• Bleeding time and PFA-100 (platelet function analyzer) are not advised for VWD screening due to poor sensitivity, specificity, and reproducibility. 1, 2